Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice.
Venkatachalapathy P et al.
Pharmacogenomics and Personalized Medicine, 2021
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross-Sectional Study.
Wu K et al.
International Journal of Endocrinology, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins.
Molnár J et al.
Plos One, 2016
The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Kashi Z et al.
Diabetes Research and Clinical Practice, 2015
Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine.
Choi CI et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2013
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes.
Cheong HS et al.
Journal of Human Genetics, 2011
Possible association of SLC22A2 polymorphisms with aspirin-intolerant asthma.
Park TJ et al.
International Archives of Allergy and Immunology, 2011
SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
Li Q et al.
Acta Pharmacologica Sinica, 2010
Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver.
Shin HJ et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML et al.
Pharmacogenetics and Genomics, 2010
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Becker ML et al.
Diabetes, 2009
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.
Avery P et al.
Pharmacogenomics and Personalized Medicine, 2009
Genetic variants of the organic cation transporter 2 influence the disposition of metformin.
Song IS et al.
Clinical Pharmacology and Therapeutics, 2008
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.
Wang ZJ et al.
Pharmacogenetics and Genomics, 2008
Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population.
Kang HJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E et al.
Journal of Human Genetics, 2007
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.
Fujita T et al.
Journal of Pharmaceutical Sciences, 2006
Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2).
Fukushima-Uesaka H et al.
Drug Metabolism and Pharmacokinetics, 2004